Business Context and Reporting Period
Company: Nanophase Technologies Corporation (Note: Input metadata referenced "SOLESENCE, INC." but the filing text identifies the registrant as Nanophase Technologies Corporation).
Reporting Period: Fiscal year ended December 31, 2005.
Business Overview: Nanophase is a developer and commercial manufacturer of nanocrystalline materials (nanoparticles) used in sunscreens, personal care, abrasion-resistant applications, antimicrobial products, and semiconductor polishing (CMP). The company utilizes proprietary Physical Vapor Synthesis (PVS) and NanoArc synthesis technologies. Operations are conducted from facilities in Romeoville and Burr Ridge, Illinois.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Total Revenue | $6,801,907 | $5,207,934 |
| Product Revenue | $6,444,444 | $4,253,478 |
| Other Revenue | $357,463 | $954,456 |
| Cost of Revenue | $5,827,719 | $5,125,216 |
| Gross Profit | $974,188 | $1,082,718 |
| Net Loss | $(5,383,611) | $(6,446,955) |
| Net Loss Per Share (Basic/Diluted) | $(0.30) | $(0.37) |
| Cash and Cash Equivalents | $340,860 | $475,185 |
| Investments | $8,168,092 | $11,155,126 |
| Total Liquid Assets (Cash + Investments) | $8,508,952 | $11,630,311 |
| Long-Term Debt | $1,265,875 | $0 |
| Accumulated Deficit | $(57,567,641) | $(52,184,030) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30.6% to $6.8 million, driven primarily by a 51.5% increase in product revenue. This was attributed to increased sales of sunscreen materials to BASF (largest customer) and CMP materials to Rohm and Haas Electronic Materials (RHEM).
- Other Revenue Decline: Other revenue decreased 62.5% to $357,463. This was primarily due to the absence of a $600,000 technology development payment from RHEM that was recognized in 2004.
- Operating Expenses: Total operating expenses increased to $12.5 million. A one-time lease accounting adjustment of $279,810 was recorded in Q3 2005 to correct prior accounting practices regarding straight-line rent expense.
- Debt Financing: In November 2005, the company secured a $1.6 million promissory note from BYK-Chemie USA (a subsidiary of Altana) to fund additional dispersion capacity and a NanoArc synthesis reactor. This resulted in the recognition of long-term debt, which was zero in 2004.
- Net Loss Improvement: Net loss narrowed by approximately $1.06 million compared to 2004, despite the lease adjustment, due to higher revenue volume and increased interest income.
Guidance, Outlook, and Risks
- Outlook: Management expects revenue growth to continue in 2006, driven by end-user adoption in CMP and fine polishing markets, and the expansion of the relationship with Altana Chemie in coatings and sealants. A new coated sunscreen material introduced by BASF in May 2005 is expected to expand sales in European and Asian markets in 2006.
- Liquidity: The company believes cash, investments, and the proceeds from the BYK-Chemie loan will be adequate to fund operations through 2006. Capital spending for 2006 is estimated at approximately $2.0 million.
- Customer Concentration Risk: The company is highly dependent on three key customers (BASF, RHEM, and C.I. Kasei), which accounted for approximately 83% of total revenue in 2005. BASF alone accounted for 66% of revenue.
- Supply Agreement Triggers: The supply agreement with BASF contains financial covenants. If the company fails to maintain earnings greater than zero AND cash/investments above $2.0 million, or if debt maturities over $10 million are accelerated, BASF may trigger a mandatory license of technology and sale of production equipment.
- Intellectual Property: The company faces a patent re-examination regarding its NanoArc synthesis process. While the examiner initially agreed claims were patentable, a second request for re-examination was filed, and claims were amended. Narrowing of these claims could impair legal protection.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the supply agreements with BASF (66% of revenue) and RHEM, and the potential impact of losing either customer.
- Covenant Compliance: Monitor quarterly cash and investment balances to ensure they remain above the $2.0 million threshold required to avoid triggering the BASF equipment transfer clause.
- Patent Status: Track the outcome of the USPTO re-examination of Patent No. 6,669,823 B1 regarding the NanoArc synthesis process.
- Profitability Path: Assess whether the modest gross margin (approx. 14% in 2005) can expand sufficiently to cover fixed operating costs and achieve net profitability, given the history of losses.
- Debt Service: Review the terms of the $1.6 million BYK-Chemie loan, noting that interest accrues only after equipment commissioning and principal payments begin in 2009.